Document:

exv4w5a

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 4.5A

THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY

Fluidigm Corporation

a California corporation

CONVERTIBLE PROMISSORY NOTE

NOTE NUMBER E-3 (REVISED)

			
	 	 	 
	US$5,000,000
	 	April 19, 2007
	 
	 	South San Francisco, California

     1. Principal and Interest. Fluidigm Corporation (the “Company”), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the “Holder”) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365 days, compounded annually.

     This Convertible Promissory Note (“Note”) is the third Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August 7, 2006 (as amended, modified or
supplemented, the “Note Purchase Agreement”) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.

     Unless converted in accordance with Section 3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section 3). This Note may
be prepaid by Company at any time, in accordance with the terms of Section 2 of this Note. Upon
payment in full of all principal and interest payable hereunder (including upon any conversion),
this Note shall be surrendered to the Company for cancellation. All payments hereon shall be
applied first to accrued interest and second to the reduction of principal.

 

 

     2. Prepayment of Note. Upon five days prior written notice to Holder (the
“Prepayment Notice”), the Company may prepay this Note in whole or in part; provided that
any such prepayment will be applied first to the payment of expenses due under this Note, second to
interest accrued on this Note and third, if the amount of prepayment exceeds the amount of all such
expenses and accrued interest, to the payment of principal of this Note. In the event that the
Holder desires to avoid prepayment of the Note by the Company, the Holder must within five days of
its receipt of the Prepayment Notice deliver to the Company the Conversion Notice pursuant to
Section 3(c)(iii) electing to convert this Note, in which case this Note will not be prepaid as
provided in the Prepayment Notice and will instead be converted into shares of Series E Preferred
Stock of the Company in accordance with Section 3 of this Note.

     3. Conversion.

          (a) Conversion Events. Upon the earlier to occur of (i) an Initial Public Offering
(as defined below) or (ii) satisfaction of each of the Milestones pursuant to Section 3(b)(iv)
below (either, a “Conversion Event”), all of the then outstanding principal and accrued
interest owing under this Note shall convert into that number of shares of Series E Preferred Stock
of the Company determined by dividing (i) the aggregate principal and accrued interest owing under
this Note as of the date of such Conversion Event by (ii) the Conversion Price (as defined below).
Notwithstanding the foregoing, by complying with Section 3(c)(iii) hereof, the Holder may at any
time earlier elect to convert this Note into that number of shares of Series E Preferred Stock
determined by dividing (i) the aggregate principal and accrued interest owing under this Note as of
the date of the Conversion Notice (as defined in Section 3(c)(iii)) by (ii) the Conversion Price
(as defined below).

          (b) Definitions. For purposes of this Note, the following terms shall have the
following meanings:

               (i) The term “Change of Control Transaction” shall mean (i) the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii) a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.

               (ii) The term “Conversion Price” shall mean US$3.60, subject to adjustment as set
forth in Section 5 below.

               (iii) The term “Initial Public Offering” shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
“Securities Act”) after or in connection with which the outstanding shares of Preferred
Stock of the

 

 

Company have been converted into Common Stock pursuant to the Company’s then existing Articles
of Incorporation or otherwise.

               (iv) Unless otherwise agreed in writing between the Company and the Holder, the term
“Milestones” shall mean satisfaction of the following on or before April 30, 2008:

                    (1) The
Company will have released [***] to [***], as
demonstrated by a [***] approval form duly signed-off. The approval is typically
characterized by having completed [***], including [***] and [***] of
suitable [***];

                    (2) The
approved [***] (or a subsequent [***] thereof) will be [***]
generally [***] to [***], as demonstrated by a Company [***];

                    (3) The Subsidiary will also have [***] and [***]
them [***] to at [***];

                    (4) The Subsidiary will have at least [***] the [***] of [***] to achieve [***] in the First Note and the [***]
 in the Second Note; and

                    (5) The Company will be [***] the [***] through the Subsidiary in
Singapore, and the Company’s then-current [***] and [***] will provide for the
[***] of the [***] through the Subsidiary in
Singapore; [***] if the Holder provides the Company with a [***] pursuant to Section
3(c)(ii) below, then the Company shall have 30 days following the Company’s receipt of the
[***] to [***] any [***] to [***] identified by the Holder in the [***].

               (v) The term “Payment Date” shall mean April 19, 2009 or such later date as may be
mutually agreed in writing by Holder and the Company.

          (c) Conversion Procedure.

               (i) Conversion in Connection with Initial Public Offering. Upon the occurrence of an
Initial Public Offering as set forth in Section 3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.

               (ii) Conversion in Connection with Satisfaction of Milestones. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the “Milestone Completion Notice”) to the Holder (at the address last shown on the records

 

 

of the Company for the Holder or given by Holder to Company for the purpose of notice)
specifying the Conversion Price, the date on which the Company reasonably believes all of the
Milestones were satisfied (the “Notified Milestone Completion Date”), together with a duly
executed compliance certificate dated as of the Notified Milestone Completion Date substantially in
the form attached hereto as Exhibit A (the “Compliance Certificate”), and calling
upon Holder to surrender to the Company the Note. In the event that the Holder reasonably believes
that any of (i) the Milestones have not been satisfied or (ii) the representations and warranties
made in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the “Milestone Response Notice”) to the Company of such disagreement and/or
inaccuracy within 30 days of its receipt of the Milestone Completion Notice. The Milestone
Response Notice shall specify in reasonable detail the reasons for such disagreement and/or basis
for belief that any of the representations and warranties made in the Compliance Certificate are
inaccurate and shall be accompanied by reasonably available support documentation evidencing the
basis for such disagreement or belief. If the Holder shall fail to provide the Milestone Response
Notice within such time period, the Milestones shall be deemed satisfied as of the Notified
Milestone Completion Date and this Note shall be automatically converted as set forth in
Section 3(a). If the Holder shall have timely provided the Milestone Response Notice, the Company
and the Holder shall in good faith attempt to resolve their disagreement as to the satisfaction of
the Milestones and/or the accuracy of the representations and warranties in the Compliance
Certificate. If the Company and Holder are unable to resolve their disagreement within the
Milestones Cure Period, the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.

               (iii) Elective Conversion. If the Holder wishes to voluntarily convert this Note as
set forth in Section 3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the “Conversion Notice”) to
that effect.

               (iv) Certificate; Time of Conversion. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section 3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section 3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section 3(c)(iii), upon the Company’s receipt of
such Conversion Notice); provided, however, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.

 

 

          (d) Fractional Shares. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.

          (e) Reservation of Shares. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series E
Preferred Stock or other securities to permit the full conversion of the outstanding principal and
interest of this Note pursuant to the terms of this Note. In the event the Company shall have
insufficient shares of Series E Preferred Stock or other securities to permit the full conversion
of the outstanding principal and accrued interest of this Note pursuant to the terms hereof, the
Company hereby covenants and agrees that the Company shall use its commercially reasonable efforts
to seek board and shareholder approval of an amendment to the Company’s Articles of Incorporation
in order to authorize an increase in the number of authorized shares of Series E Preferred Stock or
other securities of the Company in a sufficient amount so that the aggregate number of shares of
Series E Preferred Stock or other securities issuable upon conversion of this Note will then be
authorized and available for issuance.

     4. Change of Control Transaction. The Company shall provide the Holder with 15 days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section 3(c)(iii) within such 15 day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.

     5. Change in Series E Preferred Stock.

          (a) Split, Subdivision or Combination of Series E Preferred Stock. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such

 

 

decrease in outstanding shares of Series E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable.

          (b) Reclassification etc. In case of any reclassification, capital reorganization, or
change in the Series E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company’s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section 5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
that this Note shall be convertible upon the terms set forth herein into the kind and amount of
shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series E
Preferred Stock or other securities as are issuable on conversion of this Note.

          (c) Merger or Consolidation. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.

     6. Payment Due Date. If not previously converted into shares of Series E Preferred
Stock pursuant to Section 3 hereof and if not sooner prepaid by the Company pursuant to Section 2
hereof or accelerated and declared due and owing by the Holder pursuant to Section 7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.

     7. Default. The Company shall be deemed to be in default under this Note in the event
(i) the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section 4 of the Note Purchase Agreement for a period of 30 days after written notice of such
failure from Holder; (ii) the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii) the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,

 

 

demand, protest, or further notice of any kind, as well as enforce all other rights and
remedies available to the Holder under applicable law.

     8. Notices. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:

	 	 	 	 	 
	 
	 	If to Holder:	 	Biomedical Sciences Investment Fund Pte Ltd
	 
	 	 	 	20 Biopolis Way
	 
	 	 	 	#09-01 Centros
	 
	 	 	 	Singapore 138668
	 
	 	 	 	Attention: Chu Swee Yeok
	 
	 	 	 	Tel:  65-6336-2288
	 
	 	 	 	Fax:  65-6334-8478
	 
	 	 	 	 
	 
	 	If to the Company:	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, California  94080
	 
	 	 	 	Attention:  Chief Executive Officer
	 
	 	 	 	Tel:  (650) 266-6000
	 
	 	 	 	Fax: (650) 871-7195
	 
	 	 	 	 
	 
	 	 	 	with a copy to:
	 
	 	 	 	 
	 
	 	 	 	Wilson Sonsini Goodrich & Rosati, P.C.
	 
	 	 	 	650 Page Mill Road
	 
	 	 	 	Palo Alto, California  94304-1050
	 
	 	 	 	Attention:  Ken Clark and Robert Kornegay
	 
	 	 	 	Tel: (650) 493-9300
	 
	 	 	 	Fax: (650) 493-6811

     Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.

     9. Amendments. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.

     10. No Rights as Shareholder. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.

 

 

     11. Successors and Assigns. Subject to the restrictions on transfer described in
Section 12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.

     12. Transfer of Note and Securities Issuable on Conversion Hereof. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
transfer, pledge or other disposition of the securities into which this Note may be converted after
conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June 13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the “Rights Agreement”). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections 1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.

     13. Highest Lawful Rate. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, “Highest Lawful Rate” means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.

     14. Miscellaneous. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys’ fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder’s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to “dollars” or “$” in this Note shall refer to the lawful
money of the United States of America.

 

 

     IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.

	 	 	 	 	 	 	 
	Dated: April 19, 2007	 	Fluidigm Corporation	 	 
	 	 	a California corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Gajus V. Worthington
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Gajus Worthington
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Chief Executive Officer
 

	 	 
	 
	 	 	 	 	 	 
	Acknowledged and Agreed:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Holder	 	 
	 
	 	 	 	 	 	 
	 	 	Biomedical Sciences Investment Fund Pte Ltd	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Chu Swee Yeok
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Chu Swee Yeok
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Directorexv10w1

 

Exhibit 10.1

FLUIDIGM CORPORATION

INDEMNIFICATION AGREEMENT

     This Indemnification Agreement (“Agreement”) is made as of                     , 20     , by and between
Fluidigm Corporation, a Delaware corporation (the “Company”), and                      (“Indemnitee”).

     WHEREAS, the Company and Indemnitee recognize the significant cost of directors’ and officers’
liability insurance and the general reductions in the coverage of such insurance;

     WHEREAS, the Company and Indemnitee further recognize the substantial increase in corporate
litigation in general, subjecting officers and directors to expensive litigation risks at the same
time as the coverage of liability insurance has been severely limited; and

     WHEREAS, the Company desires to attract and retain the services of highly qualified
individuals, such as Indemnitee, to serve as officers and directors of the Company and to indemnify
its officers and directors so as to provide them with the maximum protection permitted by law.

     NOW, THEREFORE, in consideration for Indemnitee’s services as an officer or director of the
Company, the Company and Indemnitee hereby agree as follows:

     1. Indemnification.

          (a) Third Party Proceedings. The Company shall indemnify Indemnitee if Indemnitee was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit,
proceeding or any alternative dispute resolution mechanism, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the Company) by reason of the fact
that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary
of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines
and amounts paid in settlement (if such settlement is approved in advance by the Company, which
approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in
connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s
conduct was unlawful. The termination of any action, suit or proceeding by judgment, order,
settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself,
create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company, and, with respect
to any criminal action or proceeding, had reasonable cause to believe that Indemnitee’s conduct was
unlawful.

          (b) Proceedings By or in the Right of the Company. The Company shall indemnify Indemnitee if
Indemnitee was or is a party or is threatened to be made a party to any threatened,

 

 

pending or completed action or suit by or in the right of the Company or any subsidiary of the
Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a
director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason
of the fact that Indemnitee is or was serving at the request of the Company as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses (including attorneys’ fees) and, to the fullest extent permitted by law, amounts
paid in settlement actually and reasonably incurred by Indemnitee in connection with the defense or
settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company, except that no
indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall
have been adjudged to be liable to the Company unless and only to the extent that the Court of
Chancery of the State of Delaware or the court in which such action or suit was brought shall
determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery of the State of Delaware or such other court shall deem
proper.

          (c) Mandatory Payment of Expenses. To the extent that Indemnitee has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in Subsections (a) and
(b) of this Section 1, or in defense of any claim, issue or matter therein, Indemnitee shall be
indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by
Indemnitee in connection therewith.

     2. Expenses; Indemnification Procedure.

          (a) Advancement of Expenses. The Company shall advance all expenses actually and reasonably
incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any
civil or criminal action, suit or proceeding referenced in Section 1(a) or 1(b) hereof (but not
amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby
undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be
determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby.
The advances to be made hereunder shall be paid by the Company to Indemnitee within thirty (30)
days following delivery of a written request therefor by Indemnitee to the Company.

          (b) Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to his right
to be indemnified under this Agreement, give the Company notice in writing as soon as practicable
of any claim made against Indemnitee for which indemnification will or could be sought under this
Agreement. Notice to the Company shall be directed to the President of the Company at the address
shown on the signature page of this Agreement (or such other address as the Company shall designate
in writing to Indemnitee). Notice shall be deemed received three business days after the date
postmarked if sent by domestic certified or registered mail, properly addressed; otherwise notice
shall be deemed received when such notice shall actually be received by the Company. In addition,
Indemnitee shall give the Company such information and cooperation as it may reasonably require and
as shall be within Indemnitee’s power.

- 2 -

 

          (c) Procedure. Any indemnification and advances provided for in Section 1 and this Section 2
shall be made no later than thirty (30) days after receipt of the written request of Indemnitee. If
a claim under this Agreement, under any statute, or under any provision of the Company’s
Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the
Company within thirty (30) days after a written request for payment thereof has first been received
by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the
Company to recover the unpaid amount of the claim and, subject to Section 12 of this Agreement,
Indemnitee shall also be entitled to be paid for the reasonable expenses (including reasonable
attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an
action brought to enforce a claim for expenses incurred in connection with any action, suit or
proceeding in advance of its final disposition) that Indemnitee has not met the standards of
conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for
the amount claimed. However, Indemnitee shall be entitled to receive interim payments of expenses
pursuant to Subsection 2(a) unless and until such defense may be finally adjudicated by court order
or judgment from which no further right of appeal exists. It is the parties’ intention that if the
Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to
indemnification shall be for the court to decide, and neither the failure of the Company (including
its Board of Directors, any committee or subgroup of the Board of Directors, independent legal
counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is
proper in the circumstances because Indemnitee has met the applicable standard of conduct required
by applicable law, nor an actual determination by the Company (including its Board of Directors,
any committee or subgroup of the Board of Directors, independent legal counsel, or its
stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a
presumption that Indemnitee has or has not met the applicable standard of conduct.

          (d) Notice to Insurers. If, at the time of the receipt of a notice of a claim pursuant to
Section 2(b) hereof, the Company has director and officer liability insurance in effect, the
Company shall give prompt notice of the commencement of such proceeding to the insurers in
accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee,
all amounts payable as a result of such proceeding in accordance with the terms of such policies.

          (e) Selection of Counsel. In the event the Company shall be obligated under Section 2(a)
hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall
be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, which
approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of
its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and
the retention of such counsel by the Company, the Company will not be liable to Indemnitee under
this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same
proceeding; provided that Indemnitee shall have the right to employ Indemnitee’s counsel in any
such proceeding at Indemnitee’s expense; and provided further that if (i) the Company has expressly
authorized (and continues to authorize) the employment of counsel by Indemnitee at the Company’s
expense, (ii) the use of counsel chosen by the Company to represent Indemnitee would present such
counsel with a conflict of interest, or (iii) the Company shall not, in fact, have employed counsel
reasonably satisfactory to Indemnitee within a reasonable time after notice of the institution of
such

- 3 -

 

proceeding, Indemnitee shall have the right to employ counsel at the expense of the Company in
accordance herewith.

     3. Additional Indemnification Rights; Nonexclusivity.

          (a) Scope. Notwithstanding any other provision of this Agreement, the Company hereby agrees to
indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such
indemnification is not specifically authorized by the other provisions of this Agreement, the
Company’s Certificate of Incorporation, the Company’s Bylaws or by statute. In the event of any
change, after the date of this Agreement, in any applicable law, statute, or rule which expands the
right of a Delaware corporation to indemnify a member of its board of directors or an officer, such
changes shall be, ipso facto, within the purview of Indemnitee’s rights and Company’s obligations,
under this Agreement. In the event of any change in any applicable law, statute or rule which
narrows the right of a Delaware corporation to indemnify a member of its board of directors or an
officer, such changes, to the extent not otherwise required by such law, statute or rule to be
applied to this Agreement shall have no effect on this Agreement or the parties’ rights and
obligations hereunder.

          (b) Nonexclusivity. The indemnification provided by this Agreement shall not be deemed
exclusive of any rights to which Indemnitee may be entitled under the Company’s Certificate of
Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested Directors, the
General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee’s
official capacity and as to action in another capacity while holding such office. The
indemnification provided under this Agreement shall continue as to Indemnitee for any action taken
or not taken while serving in an indemnified capacity even though he may have ceased to serve in
such capacity at the time of any action, suit or other covered proceeding.

     4. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties
actually or reasonably incurred by him in the investigation, defense, appeal or settlement of any
civil or criminal action, suit or proceeding, but not, however, for the total amount thereof, the
Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines
or penalties to which Indemnitee is entitled.

     5. Mutual Acknowledgement. Both the Company and Indemnitee acknowledge that in certain
instances, Federal law or applicable public policy may prohibit the Company from indemnifying its
directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges
that the Company has undertaken or may be required in the future to undertake with the Securities
and Exchange Commission to submit the question of indemnification to a court in certain
circumstances for a determination of the Company’s right under public policy to indemnify
Indemnitee.

     6. Officer and Director Liability Insurance. The Company shall, from time to time, make the
good faith determination whether or not it is practicable for the Company to obtain and maintain a
policy or policies of insurance with reputable insurance companies providing the officers and
directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s

- 4 -

 

performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance coverage against the
protection afforded by such coverage. In all policies of director and officer liability insurance,
Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights
and benefits as are accorded to the most favorably insured of the Company’s directors, if
Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the
Company but is an officer. Notwithstanding the foregoing, the Company shall have no obligation to
obtain or maintain such insurance if the Company determines in good faith that such insurance is
not reasonably available, if the premium costs for such insurance are disproportionate to the
amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so
as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained
by a subsidiary or parent of the Company.

     7. Severability. Nothing in this Agreement is intended to require or shall be construed as
requiring the Company to do or fail to do any act in violation of applicable law. The Company’s
inability, pursuant to court order, to perform its obligations under this Agreement shall not
constitute a breach of this Agreement. The provisions of this Agreement shall be severable as
provided in this Section 7. If this Agreement or any portion hereof shall be invalidated on any
ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify
Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not
have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in
accordance with its terms.

     8. Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall
not be obligated pursuant to the terms of this Agreement:

          (a) Claims Initiated by Indemnitee. To indemnify or advance expenses to Indemnitee with
respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of
defense, except with respect to proceedings brought to establish or enforce a right to
indemnification under this Agreement or any other statute or law or otherwise as required under
Section 145 of the Delaware General Corporation Law, but such indemnification or advancement of
expenses may be provided by the Company in specific cases if the Board of Directors has approved
the initiation or bringing of such suit; or

          (b) Lack of Good Faith. To indemnify Indemnitee for any expenses incurred by the Indemnitee
with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if
a court of competent jurisdiction determines that each of the material assertions made by the
Indemnitee in such proceeding was not made in good faith or was frivolous; or

          (c) Insured Claims. To indemnify Indemnitee for expenses or liabilities of any type whatsoever
(including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid
in settlement) which have been paid directly to Indemnitee by an insurance carrier under a policy
of officers’ and directors’ liability insurance maintained by the Company.

          (d) Claims Under Section 16(b). To indemnify Indemnitee for expenses and the payment of
profits arising from the purchase and sale by Indemnitee of securities in violation of
Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute.

- 5 -

 

     9. Construction of Certain Phrases.

          (a) For purposes of this Agreement, references to the “Company” shall include, in addition to
the resulting corporation, any constituent corporation (including any constituent of a constituent)
absorbed in a consolidation or merger which, if its separate existence had continued, would have
had power and authority to indemnify its directors, officers, and employees or agents, so that if
Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is
or was serving at the request of such constituent corporation as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee
shall stand in the same position under the provisions of this Agreement with respect to the
resulting or surviving corporation as Indemnitee would have with respect to such constituent
corporation if its separate existence had continued.

          (b) For purposes of this Agreement, references to “other enterprises” shall include employee
benefit plans; references to “fines” shall include any excise taxes assessed on Indemnitee with
respect to an employee benefit plan; and references to “serving at the request of the Company”
shall include any service as a director, officer, employee or agent of the Company which imposes
duties on, or involves services by, such director, officer, employee or agent with respect to an
employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith
and in a manner Indemnitee reasonably believed to be in the interest of the participants and
beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner
“not opposed to the best interests of the Company” as referred to in this Agreement.

     10. Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall constitute an original.

     11. Successors and Assigns. This Agreement shall be binding upon the Company and its
successors and assigns, and shall inure to the benefit of Indemnitee and Indemnitee’s estate,
heirs, legal representatives and assigns.

     12. Attorneys’ Fees. In the event that any action is instituted by Indemnitee under this
Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid
all court costs and expenses, including attorneys’ fees, actually and reasonably incurred by
Indemnitee with respect to such action, unless as a part of such action, the court of competent
jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such
action were not made in good faith or were frivolous. In the event of an action instituted by or in
the name of the Company under this Agreement or to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including
attorneys’ fees, actually and reasonably incurred by Indemnitee in defense of such action
(including with respect to Indemnitee’s counterclaims and cross-claims made in such action), unless
as a part of such action the court determines that each of Indemnitee’s material defenses to such
action were made in bad faith or were frivolous.

     13. Notice. All notices, requests, demands and other communications under this Agreement shall
be in writing and shall be deemed duly given (i) if delivered by hand and receipted for by the
party addressee, on the date of such receipt, or (ii) if mailed by domestic certified or registered
mail

- 6 -

 

with postage prepaid, on the third business day after the date postmarked. Addresses for
notice to either party are as shown on the signature page of this Agreement, or as subsequently
modified by written notice.

     14. Consent to Jurisdiction. The Company and Indemnitee each hereby irrevocably consent to the
jurisdiction of the courts of the State of Delaware for all purposes in connection with any action
or proceeding which arises out of or relates to this Agreement and agree that any action instituted
under this Agreement shall be brought only in the state courts of the State of Delaware.

     15. Choice of Law. This Agreement shall be governed by and its provisions construed in
accordance with the laws of the State of Delaware, as applied to contracts between Delaware
residents entered into and to be performed entirely within Delaware without regard to the conflict
of law principles thereof.

     16. Period of Limitations. No legal action shall be brought and no cause of action shall be
asserted by or in the right of the Company against Indemnitee, Indemnitee’s estate, spouse, heirs,
executors or personal or legal representatives after the expiration of two years from the date of
accrual of such cause of action, and any claim or cause of action of the Company shall be
extinguished and deemed released unless asserted by the timely filing of a legal action within such
two-year period; provided, however, that if any shorter period of limitations is otherwise
applicable to any such cause of action, such shorter period shall govern.

     17. Subrogation. In the event of payment under this Agreement, the Company shall be subrogated
to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all
documents required and shall do all acts that may be necessary to secure such rights and to enable
the Company effectively to bring suit to enforce such rights.

     18. Amendment and Termination. No amendment, modification, termination or cancellation of this
Agreement shall be effective unless it is in writing signed by both the parties hereto. No waiver
of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing
waiver.

     19. Integration and Entire Agreement. This Agreement sets forth the entire understanding
between the parties hereto and supersedes and merges all previous written and oral negotiations,
commitments, understandings and agreements relating to the subject matter hereof between the
parties hereto.

(signature page follows)

- 7 -

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	FLUIDIGM CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Signature of Authorized Signatory	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Print Name	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Address:
	 	7000 Shoreline Court, Suite 100	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	South San Francisco, CA 94080	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	AGREED TO AND ACCEPTED:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	INDEMNITEE:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Signature	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Print Name	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Title	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]